香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 總收益由截至2024年6月30日止六個月的人民幣419.7百萬元增加74.3%至截至 2025年6月30日止六個月的人民幣731.4百萬元，主要是由於奧布替尼銷量增 長強勁及來自Prolium的許可收益。奧布替尼的收益由截至2024年6月30日止六 個月的人民幣417.0百萬元增加52.8%至截至2025年6月30日止六個月的人民幣 637.3百萬元，是由於覆蓋範圍拓寬及治療患者增加所致。 – 2 – 總運營開支（包括銷售及分銷開支、研發開支及行政開支）由截至2024年6月 30日止六個月的人民幣669.5百萬元增加17.8%至截至2025年6月30日止六個月 的人民幣788.5百萬元。該變動主要因以下各項導致：(i)銷售及分銷開支由截 至2024年6月30日止六個月的人民幣157.2百萬元增至截至2025年6月30日止六 個月的人民 ...

Core Viewpoint - The company, 诺诚健华, reported a significant increase in total revenue and a substantial reduction in losses for the six months ending June 30, 2025, primarily driven by strong sales of 奥布替尼 and licensing revenue from Prolium [1][2] Financial Performance - Total revenue increased by 74.3% to RMB 730 million compared to the same period last year [1] - Revenue from 奥布替尼 rose by 52.8% from RMB 417 million to RMB 637 million, attributed to an expanded coverage and an increase in treated patients [1] - Losses decreased by 86.7% from RMB 268 million to RMB 35.6 million during the same period [1] - Cash and cash equivalents stood at approximately RMB 7.7 billion as of June 30, 2025, providing the company with a robust financial position to accelerate clinical development and invest in competitive product lines [1] Product Development and Milestones - The company achieved significant milestones in product line advancement, including the approval of 奥布替尼 for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2] - The combination therapy of坦昔妥单抗 and 来那度胺 was approved for adult patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplantation (ASCT) [2] - The BCL-2 inhibitor ICP-248 (mesutoclax) entered two registrational clinical studies, and the company's proprietary ADC platform made significant breakthroughs with the first IND submission and clinical trial approval [2] Strategic Partnerships and Global Expansion - The company expanded its global footprint through strategic collaborations, including a partnership with Prolium in January 2025 to explore the global potential of a CD3×CD20 bispecific antibody [2] - The company remains committed to fostering global partnerships to enhance innovation, maximize the value of its product lines, and support long-term development [2] Commercial Execution - Strong commercial execution is evident with increased market penetration and significant revenue growth from 奥布替尼, highlighting the company's ability to translate scientific innovation into sustainable business performance [2]

Core Insights - The company reported a significant increase in total revenue, rising 74.3% to RMB 730 million for the six months ending June 30, 2025, primarily driven by strong sales of Oubatinib and licensing revenue from Prolium [1] - The loss for the period decreased by 86.7% to RMB 35.6 million, compared to a loss of RMB 268 million for the same period ending June 30, 2024 [1] - The company has a robust cash position of approximately RMB 7.7 billion as of June 30, 2025, allowing for flexible clinical development and investment in competitive product lines [1] Product Development and Milestones - The company achieved significant milestones in product line advancement, including the approval of Oubatinib for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2] - The combination therapy of Tanshituzumab and Lenalidomide was approved for adult patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplantation (ASCT) [2] - The BCL-2 inhibitor ICP-248 (mesutoclax) entered two registrational clinical studies, and the company's proprietary ADC platform made significant breakthroughs with the first IND submission and clinical trial approval [2] Strategic Partnerships and Market Execution - The company expanded its global footprint through strategic collaborations, including a partnership with Prolium in January 2025 to explore the global potential of a CD3×CD20 bispecific antibody [2] - The commercial execution remains strong, with increased market penetration and substantial revenue growth for Oubatinib, highlighting the company's ability to translate scientific innovation into sustainable business performance [2]

诺诚健华(09969)发布截至2025年6月30日止6个月中期业绩，该集团取得收益人民币7.31亿元(单位下 同)，同比增加74.26%;期内经调整亏损1550.4万元，同比减少93.62%;母公司拥有人应占亏损3009.1万 元，同比减少88.51%;每股亏损0.02元。 公告称，收入增加主要是由于奥布替尼销量增长强劲及来自Prolium的许可收益。奥布替尼的收益由截 至2024年6月30日止6个月的4.17亿元增加52.8%至截至2025年6月30日止6个月的 6.37亿元，是由于覆盖 范围拓宽及治疗患者增加所致。 ...

公告称，收入增加主要是由于奥布替尼销量增长强劲及来自Prolium的许可收益。奥布替尼的收益由截 至2024年6月30日止6个月的4.17亿元增加52.8%至截至2025年6月30日止6个月的 6.37亿元，是由于覆盖 范围拓宽及治疗患者增加所致。 智通财经APP讯，诺诚健华(09969)发布截至2025年6月30日止6个月中期业绩，该集团取得收益人民币 7.31亿元(单位下同)，同比增加74.26%;期内经调整亏损1550.4万元，同比减少93.62%;母公司拥有人应占 亏损3009.1万元，同比减少88.51%;每股亏损0.02元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 截至2025年6月30日止六個月中期業績公告 諾誠健華醫藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）欣然公佈，本集團截至2025年6月30日止六個月（「報告期」） 之未經審核綜合業績連同截至2024年6月30日止六個月之比較數字。 在本公告內，「我們」及「我們的」均指本公司，如文義另有所指，則指本集團。 本公告所載若干金額及百分比數字已約整或已四捨五入至小數點後一位或兩 位數（如適用）。任何表格、圖表或其他地方所示總額與所列數額總和如有任何 差異乃因四捨五入所致。除另有界定外，本公告所使用詞彙與招股章程已界定 者具有相同涵義。 – 1 – | 財務摘要 | | | | --- | --- | --- | ...

Core Viewpoint - The emergence of "technical managers" as a bridge between scientific research and market needs is transforming the employment landscape in the context of technological innovation and entrepreneurship [2][8]. Group 1: Industry Trends - Technology-driven and knowledge-intensive entrepreneurship has become a significant trend in recent years, with many researchers aspiring to transition from PI (Principal Investigator) to IP (Innovation Project) and eventually to IPO (Initial Public Offering) [2]. - The formal recognition of "technical managers" as a profession in the national occupational classification system in 2022 marks a shift towards professionalization and specialization in this role [2][8]. Group 2: Regional Developments - In July 2023, Shenzhen recognized its first batch of 154 "senior professional technical managers" from 133 different institutions, indicating a growing emphasis on this role in the region [3][15]. - The establishment of the first "Technical Manager Academy" at Shenzhen Technology University aims to cultivate a new generation of technical managers, with a focus on interdisciplinary education [14]. Group 3: Challenges in Scientific Entrepreneurship - Many scientists face challenges in entrepreneurship due to a lack of market insight, often focusing solely on technological advancements rather than market needs, leading to high failure rates in startups [5][6]. - The need for effective collaboration between scientists and technical managers is emphasized, as the latter can help translate scientific innovations into commercially viable products [8][11]. Group 4: Educational Initiatives - Several universities, including Tsinghua University and Shanghai Jiao Tong University, have begun offering specialized master's programs in technology transfer to address the shortage of qualified technical managers [14]. - The "Five Forces Model" proposed for training technical managers includes skills in technology, market insight, finance, law, and management, highlighting the multifaceted nature of the role [9][10]. Group 5: Future Outlook - The goal set by the Ministry of Science and Technology is to exceed 30,000 technical managers nationwide by 2025, reflecting the increasing importance of this role in facilitating technology transfer and commercialization [9]. - Shenzhen's dual approach of professional recognition and educational development is expected to provide a model for enhancing technology transfer capabilities across the country [15].

Core Viewpoint - Nocera Biopharma (09969) shares rose over 3%, currently up 3.5% at HKD 18.63, with a trading volume of HKD 133 million, ahead of the board meeting scheduled for August 19 to approve mid-term results [1] Group 1: Financial Performance - Nocera Biopharma's first-quarter revenue increased by 130% year-on-year, with net profit turning positive at HKD 1.8 billion, exceeding expectations due to strong growth of its core product, Oubreti, and confirmation of upfront payment from Prolium [1] - CICC has revised its profit forecasts for Nocera Biopharma, narrowing expected losses for the next two years from HKD 436 million and HKD 256 million to HKD 415 million and HKD 225 million, respectively [1] Group 2: Product Insights - Oubreti, a BTK inhibitor developed by Nocera Biopharma, is primarily used for treating chronic lymphocytic leukemia and is gaining market share, holding a significant position in the domestic BTK inhibitor market [1] - In 2024, Oubreti's sales revenue is projected to exceed HKD 1 billion, representing a year-on-year growth of 49.14%, capturing a 30% market share in the domestic BTK inhibitor market [1]

Core Viewpoint - Nocera Health (09969) has seen a stock increase of over 3%, currently at 18.63 HKD, with a trading volume of 133 million HKD, ahead of its board meeting scheduled for August 19 to approve mid-term results [1] Financial Performance - Nocera Health's first-quarter revenue increased by 130% year-on-year, with net profit turning positive at 1.8 billion HKD, exceeding expectations due to strong growth of its core product, Oubreti [1] - CICC has revised its profit forecasts for Nocera Health, narrowing expected losses for the next two years from 436 million HKD and 256 million HKD to 415 million HKD and 225 million HKD respectively [1] Product Insights - Oubreti, a BTK inhibitor developed by Nocera Health, is primarily used for treating chronic lymphocytic leukemia and has been gaining market share, holding a significant position in the domestic BTK inhibitor market [1] - In 2024, Oubreti's sales revenue is projected to exceed 1 billion HKD, representing a year-on-year growth of 49.14%, capturing a 30% market share in the domestic BTK inhibitor market [1]

Group 1 - The core viewpoint of the article highlights the positive impact of rising expectations for interest rate cuts in the US on the biotechnology sector, leading to a significant increase in the S&P Biotechnology Index by 2.89% [1] - The Hong Kong pharmaceutical sector continues to show strong performance, with the Hong Kong Pharmaceutical ETF (159718.SZ) rising by 0.38% [1] - Notable individual stock performances include a 6.22% increase for Simcere Pharmaceutical Group (02410), a 3.34% rise for BeiGene (06160), and a 2.29% increase for Kelun-Biotech (06990) [1] Group 2 - The liquidity in the market is robust, with the Hong Kong Pharmaceutical ETF seeing a turnover of 13.3% and a transaction volume of 36.42 million yuan within the first 20 minutes of trading [1] - Guotai Junan Securities has stated that China's innovative drugs are on the rise, entering the initial phase of realizing innovation results, with significant opportunities for independent development and large transactions through business development (BD) licensing [1] - The Hong Kong Pharmaceutical ETF focuses on 18 A-share biotechnology companies, including key innovative drug firms such as BeiGene, WuXi Biologics, and CSPC Pharmaceutical Group, benefiting from global innovation drug research dividends [1] Group 3 - The article emphasizes the favorable conditions for the innovative drug growth sector due to the anticipated US interest rate cuts, which are expected to benefit the domestic innovative drug companies as they expand internationally [1] - The recommendation is to pay attention to the Hong Kong Pharmaceutical ETF (159718.SZ) and its associated funds (Class A: 019598, Class C: 019599) as they are positioned to capitalize on these trends [1]